Bedaquiline has potential for targeting tuberculosis reservoirs in the central nervous system

Bedaquiline (BDQ) is the first-in-class United States Food and Drug Administration (US FDA) approved anti-tuberculosis (anti-TB) drug, which is a novel diarylquinoline antibiotic that has recently been utilized as an effective adjunct to existing therapies for multidrug-resistant tuberculosis (MDR-T...

Descripción completa

Detalles Bibliográficos
Autores principales: Pamreddy, Annapurna, Baijnath, Sooraj, Naicker, Tricia, Ntshangase, Sphamandla, Mdanda, Sipho, Lubanyana, Hlengekile, Kruger, Hendrik G., Govender, Thavendran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Royal Society of Chemistry 2018
Materias:
Chemistry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9079262/
https://www.ncbi.nlm.nih.gov/pubmed/35539382
http://dx.doi.org/10.1039/c8ra00984h

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9079262/
https://www.ncbi.nlm.nih.gov/pubmed/35539382
http://dx.doi.org/10.1039/c8ra00984h

Ejemplares similares